argenx
ISIN US04016X1019
|WKN A2H9WD
Overview
Description
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Breda, the Netherlands.
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals Netherlands
Financials
Key metrics
| Market capitalisation, EUR | 20,759.28 m |
| EPS, EUR | - |
| P/B ratio | 5.39 |
| P/E ratio | - |
| Dividend yield | 0.00% |
Income statement (2023)
| Revenue, EUR | 1,136.08 m |
| Net income, EUR | -273.34 m |
| Profit margin | -24.06% |
What ETF is argenx in?
There are 18 ETFs which contain argenx. All of these ETFs are listed in the table below. The ETF with the largest weighting of argenx is the First Trust NYSE Arca Biotechnology UCITS ETF Acc.
| ETF | Weight | Investment focus | Holdings | TER | Fund size (in m EUR) | Return 1Y | WKN | ISIN |
|---|---|---|---|---|---|---|---|---|
| Amundi Prime Global UCITS ETF DR (D) | 0.03% | Equity World | 1,475 | 0.05% | 688 | +26.37% | A2PBLJ | LU1931974692 |
| Xtrackers World Net Zero Pathway Paris Aligned UCITS ETF 1C | 0.07% | Equity World Social/Environmental Climate Change | 1,106 | 0.19% | 25 | +23.14% | DBX0RU | IE000UZCJS58 |
| First Trust NYSE Arca Biotechnology UCITS ETF Acc | 3.41% | Equity United States Health Care Biotech | 30 | 0.60% | 7 | -2.21% | A2PZBP | IE00BL0L0H60 |
| Invesco Nasdaq Next Generation 100 UCITS ETF Acc | 0.82% | Equity United States Technology | 104 | 0.25% | 41 | +17.45% | A2QPVX | IE00BMD8KP97 |
| Amundi Prime Europe UCITS ETF DR (D) | 0.20% | Equity Europe | 445 | 0.05% | 55 | +13.50% | A2PBLF | LU1931974262 |
| L&G Gerd Kommer Multifactor Equity UCITS ETF USD Distributing | 0.02% | Equity World Multi-Factor Strategy | 3,070 | 0.50% | 37 | - | WELT0B | IE000FPWSL69 |
| Xtrackers EMU Net Zero Pathway Paris Aligned UCITS ETF 1C | 0.78% | Equity Europe Social/Environmental Climate Change | 157 | 0.15% | 17 | +13.51% | DBX0RW | IE000Y6L6LE6 |
| iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 1.25% | Equity United States Health Care Biotech | 222 | 0.35% | 32 | +2.62% | A2JDYM | IE00BDZVHG35 |
| L&G Gerd Kommer Multifactor Equity UCITS ETF USD Accumulating | 0.02% | Equity World Multi-Factor Strategy | 3,070 | 0.50% | 196 | - | WELT0A | IE0001UQQ933 |
| iShares Nasdaq US Biotechnology UCITS ETF | 1.25% | Equity United States Health Care Biotech | 222 | 0.35% | 416 | +3.15% | A2DWAW | IE00BYXG2H39 |
| L&G Global Equity UCITS ETF | 0.04% | Equity World Social/Environmental | 1,237 | 0.10% | 106 | +25.80% | A2N4PQ | IE00BFXR5S54 |
| L&G Europe ex UK Equity UCITS ETF | 0.29% | Equity Europe Social/Environmental | 347 | 0.10% | 264 | +14.33% | A2N4PS | IE00BFXR5V83 |
| Amundi Prime Eurozone UCITS ETF DR (C) | 0.45% | Equity Europe | 214 | 0.05% | 57 | +16.28% | A2PWMJ | LU2089238112 |
| Amundi Prime Eurozone UCITS ETF DR (D) | 0.45% | Equity Europe | 214 | 0.05% | 44 | +16.35% | A2PBLH | LU1931974429 |
| Xtrackers Europe Net Zero Pathway Paris Aligned UCITS ETF 1C | 0.34% | Equity Europe Social/Environmental Climate Change | 329 | 0.15% | 5 | +11.80% | DBX0SQ | IE0001JH5CB4 |
| Amundi Prime All Country World UCITS ETF DIST (D) | 0.02% | Equity World | 1,109 | 0.07% | 97 | - | ETF150 | IE0009HF1MK9 |
| Amundi Prime Europe UCITS ETF DR (C) | 0.20% | Equity Europe | 445 | 0.05% | 29 | +13.66% | A2PWMH | LU2089238039 |
| Amundi Prime Global UCITS ETF DR (C) | 0.03% | Equity World | 1,475 | 0.05% | 307 | +26.47% | A2PWMK | LU2089238203 |
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.